Tickerover
Healthcare

INCY Stock Analysis

Incyte Corporation · current price $124.39 (-2.61% today)

Top-tier setup — 38% revenue growth, 3/4 EPS beats, 28% net margin. Momentum, fundamentals and macro indicators are aligned.
★★★★★
Top Tier
📊

The six-pillar scorecard

Momentum
65
Drifting higher
price trend
Growth
26
Barely growing
sales & profit growth
Quality
100
High quality
profitability & balance sheet
Valuation
20
Expensive
is the price fair?
Sentiment
32
Out of favour
analyst & crowd mood
Risk
77
Low risk
volatility & drawdown

Each pillar is scored 0-100 inside the stock’s own peer group, so a chipmaker is measured against chipmakers. These are quality descriptors, not buy or sell signals.

📉

The picture

What drove the scoreThe seven components contributing most, each read out of 100.
GrowthGrowth: 8888RSI zoneRSI zone: 100100Trend strengthTrend strength: 100100Relative strengthRelative strength: 85851-month momentum1-month momentum: 5050Earnings qualityEarnings quality: 8888Earnings accelerationEarnings acceleration: 100100
Margin profileWhat survives each step down the income statement.
GrossGross: 55.7%55.7%OperatingOperating: 41.9%41.9%NetNet: 27.7%27.7%Free cash flowFree cash flow: 32.5%32.5%
EPS surpriseReported EPS against estimate, last four quarters.
2026-06: +44.0% vs estimate+44%2026-062026-03: +35.1% vs estimate+35%2026-032025-12: -6.1% vs estimate-6%2025-122025-09: +38.0% vs estimate+38%2025-09
👁

Hype Check

Reading INCY’s price and volume history…

The audit — what has to hold for this thesis

Checking the areas that decide this thesis…

AI-generated from the company’s own filings and recent coverage, and it can be incomplete or wrong. A PASS is a reading of the cited evidence, not a verified fact and not a reason to buy. Follow each citation to the source.

🛡

Dilution Check

Reading INCY’s filings…

📣

Latest earnings

LAST EARNINGS Incyte Corporation (INCY)

Latest earnings

EPS
$2.26 vs $1.64 est · +38.0% vs estimate BEAT
Revenue
$1.67B · +22.6% YoY
Stock reaction (1M)
+1.1%
Beat streak
3 of last 4 quarters
💰

Valuation

P/E
15.8×
Forward P/E
13.9×
PEG
30.82
Price / Sales
4.3×
Price / Book
3.9×
EV / EBITDA
10.7×
Analyst target
$127.12
Target range
$86.00 – $155.00
Implied upside
+2.2%
🩺

Financial health

Gross margin
55.7%
Operating margin
41.9%
Net margin
27.7%
FCF margin
32.5%
Return on equity
30.7%
Debt / equity
0.01
Revenue growth YoY
+37.7%
EPS growth YoY
+37.7%
📈

Technicals

$81.0952-week range$132.60
RSI (14)
54
50-day MA
$118.62
200-day MA
$104.21
ATR (14)
3.14
Beta
0.77
1-month return
+1.1%
🗓️

Earnings

QuarterEPSEst.SurpriseResult
2025-09-30$2.26$1.64+38.0%Beat
2025-12-31$1.80$1.92-6.1%Miss
2026-03-31$1.81$1.34+35.1%Beat
2026-06-30$3.09$2.15+44.0%Beat
Beat 3 of the last 4 quarters.
🏛️

Ownership & risk

Short % of float
0.08%
Beta
0.77
🔗

Similar stocks in Healthcare

Frequently asked

What is INCY's Quant Score?

Incyte Corporation (INCY) currently has a TickerMover Quant Score of 75/100, rated ★★★★★ Top Tier. The Quant Score is a quantitative composite across six research pillars — momentum, quality, growth, valuation, sentiment and risk. It is research information, not investment advice.

Is Incyte Corporation (INCY) a buy?

TickerMover does not give buy or sell recommendations. INCY scores 75/100 (★★★★★ Top Tier) on our quantitative research model — a screening signal, not a personal recommendation. Do your own research, and consider an FCA-authorised adviser before investing.

How often is INCY's score updated?

INCY's Quant Score and underlying data refresh through US market hours (about every five minutes), using public market and fundamental data.

Get the full live dashboard

Real-time scoring, conflict detection, Reverse DCF and peer comparison — free while in beta.

Open the dashboard for INCY →